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Edited by Laszlo NagyAbstract Inappropriate upregulation of cyclooxygenase-2
(COX-2) and matrix metalloproteinases (MMPs) has been
implicated in the pathogenesis of various types of cancer. In
the present study, we investigated the eﬀects of hirsutenone, a
diarylheptanoid isolated from the medicinal plant Alnus hirsuta
var. sibirica, on the expression of COX-2 and MMP-9 induced
by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate
(TPA) in MCF10A human breast epithelial cells. Treatment of
MCF10A cells with TPA led to the upregulation of COX-2
and MMP-9. Hirsutenone at 12 lM inhibited the TPA-induced
COX-2 expression at both the transcriptional and posttranscrip-
tional levels. Hirsutenone also suppressed the synthesis of pros-
taglandin E2, one of the major products of COX-2, and its
catalytic activity. The upregulation of MMP-9 by TPA was also
signiﬁcantly reduced by hirsutenone. Likewise, hirsutenone
attenuated the invasiveness and motility of MCF10A cells stim-
ulated with TPA. Hirsutenone blocked the TPA-induced DNA
binding of nuclear factor kappa B (NF-jB) and translocation
of p65, the functionally active NF-jB subunit, to the nucleus.
The luciferase reporter gene assay revealed that hirsutenone
abrogated the transcriptional activity of NF-jB. Treatment of
MCF10A cells with N-alpha-Tosyl-L-phenylalanine chloro-
methyl ketone, a speciﬁc inhibitor of NF-jB, reduced the
TPA-induced expression of COX-2 and MMP-9. In summary,
hirsutenone inhibits the TPA-induced upregulation of COX-2
and MMP-9 in human breast epithelial cells, possibly by target-
ing NF-jB, which may contribute to its chemopreventive eﬀects.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Hirsutenone; Cyclooxygenase-2; Matrix
metalloproteinase-9; Human breast epithelial cells; Nuclear
factor kappa B; Invasion; MigrationAbbreviations: COX-2, cyclooxygenase-2; DMEM/F12, Dulbecco’s
modiﬁed Eagle’s medium/F-12 nutrient; MMP, matrix metallopro-
teinase; NSAID, nonsteroidal antiinﬂammatory agent; NF-jB, nuclear
factor kappa B; PGE2, prostaglandin E2; PBS, phosphate-buﬀered
saline; SDS–PAGE, sodium dodecyl sulfate–polyacrylamide gel
electrophoresis; TPA, 12-O-tetradecanoylphorbol-13-acetate; TPCK,
N-alpha-tosyl-L-phenylalanine chloromethyl ketone
*Corresponding author. Fax: +82 2 874 9775.
E-mail address: surh@plaza.snu.ac.kr (Y.-J. Surh).
1 The ﬁrst two authors contributed equally to this work.
0014-5793/$32.00  2005 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2005.12.0151. Introduction
Elevated levels of prostaglandins and enhanced cyclooxygen-
ase-2 (COX-2) activity have been frequently observed in various
transformed and cancerous cells [1]. While the constitutively ex-
pressed house-keeping enzyme COX-1 plays a pivotal role in
maintaining the homeostatic functions of a cell, the inducible
isoform COX-2 primarily mediates the inﬂammatory response
[1,2]. Overexpression of COX-2 blocks apoptosis and potenti-
ates the invasiveness of malignant cells, eﬀects that are reversed
by nonsteroidal antiinﬂammatory agents (NSAIDs) such as
celecoxib and sulindac sulﬁde [2,3]. Based on these ﬁndings,
the suppression of prostaglandin synthesis through the selective
inhibition of COX-2 has been suggested as a promising strategy
for identifying and developing chemopreventive substances [4].
Matrix metalloproteinases (MMPs) form a family of zinc-
dependent proteinases, and play a key role in the facilitation
of cancer metastasis. Among MMPs, the type IV collagenases,
such as MMP-2 (72 kDa) and MMP-9 (92 kDa), are consid-
ered to be associated with tumor cell invasion and migration
[5]. MMPs have been implicated in primary and metastatic tu-
mor growth and angiogenesis, and may even contribute to tu-
mor promotion [6,7]. Recent studies have suggested that MMP
inhibitors exert substantial protective eﬀects on tumor promo-
tion by partially blocking the expression of proinﬂammatory
enzymes, such as COX-2 [3]. Targeted inhibition of MMP thus
represents another important strategy for cancer prevention or
treatment [7,8].
Nuclear factor kappa B (NF-jB) is a ubiquitous, pleiotropic,
and multisubunit eukaryotic transcription factor. The conven-
tional active form of NF-jB is a heterodimer, which usually
consists of two protein subunits, p65 (Rel A) and p50. Other
subunits, such as Rel B, v-Rel, c-Rel, and p52, may also form
part of activated NF-jB, and it is likely that the diﬀerent forms
of NF-jB activate distinct sets of target genes. These NF-jB
complexes are activated by antigens, viruses, bacteria, inﬂam-
matory cytokines, and phorbol esters, and are potential key
targets for treating inﬂammatory conditions and some cancers
[3]. NF-jB may be one of the prime components of the intra-
cellular signaling pathways responsible for inducing the
expression of COX-2 and MMP.
There is increasing interest in identifying naturally occurring
chemopreventive substances capable of inhibiting, retarding, orblished by Elsevier B.V. All rights reserved.
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Fig. 1. The chemical structure of hirsutenone.
386 J.-H. Kim et al. / FEBS Letters 580 (2006) 385–392reversing multistage carcinogenesis [9,10]. Alnus hirsuta var.
sibirica has been used as a traditional herbal medicine for the
treatment of various diseases, including fever, hemorrhage,
diarrhea, gastroenteric disorder, lymphatic disease, and cancers
[11]. Our previous studies have demonstrated that oregonin and
hirsutanonol, pharmacologically active diarylheptanoids from
A. hirsuta var. sibirica, are potent inhibitors of inducible nitric
oxide synthase [12] and COX-2 [13]. Recently, we isolated
hirsutenone (Fig. 1), another diarylheptanoid, from the bark
of A. hirsuta var. sibirica.
Multiple lines of evidence suggest that inappropriate upregu-
lation of COX-2 and MMPs have been implicated in the devel-
opment of breast cancer [14–16]. In the present study, we
investigated the possible inhibitory eﬀect of hirsutenone on
12-O-tetradecanoylphorbol-13-acetate (TPA)-induced upregu-
lation of COX-2 and MMP-9 in MCF10A human breast epi-
thelial cells and the underlying molecular mechanisms. Here
we report that hirsutenone inhibits the TPA-induced upregula-
tion of COX-2 and MMP-9 through suppression of NF-jB
transcriptional activity in human mammary epithelial cells.2. Materials and methods
2.1. Extraction, isolation, and structural identiﬁcation of hirsutenone
Fresh bark (5.6 kg) of A. hirsuta var. sibirica was ﬁnely cut and ex-
tracted with 80% aqueous Me2CO at room temperature for three days.
Me2CO was removed in vacuo, and the aqueous solution was ﬁltered,
concentrated, and then applied to a column of Amberlite XAD-2 with
a H2O–MeOH gradient to aﬀord three fractions: I (100 g), II (60 g),
and III (80 g). Repeated column chromatography of fraction I on
Sephadex LH-20 gel and MCI gel CHP 20P with H2O–MeOH fur-
nished hirsutenone (88 mg). The structural identity of the compound
has been characterized by spectral analyses. Brown oil. [a]: 12.4
(c = 1.0, MeOH). EI MS: m/z 328 [M]+. IR cm1: 3365 (OH), 1650
(–CH‚CH–CO–), 1606, 1519 (aromatic C‚C). 1H NMR (Me2CO-
d6, 300 MHz): d 6.93 (1H, dt, J = 16.0, 8.0 Hz, H-5), 6.77–6.73 (4H
in total, m, H-20,200,5 0,500), 6.56–6.51 (2H in total, m, H-6 0,600), 6.13
(1H, d, J = 16.0 Hz, H-4), 2.82–2.47 (8H in total, m, H-1,2,6,7). 13C
NMR (acetone-d6+D2O, 75 MHz): d 201.5 (C-3), 148.5 (C-5), 146.2
(C-3 0,300), 144.4 (C-4 0,400), 134.2 (C-100), 133.9 (C-10), 131.7 (C-4),
120.7 (C-6 0,600), 116.7 (C-50,500), 116.5(C-20,200).
2.2. Materials
N-a-Tosyl-L-phenylalanine chloromethyl ketone (TPCK), cholera
toxin, hydrocortisone, antiactin antibody, and recombinant human epi-
thelial growth factor were obtained from Sigma Chemicals (St. Louis,
MO, USA). Dulbecco’s modiﬁed Eagle’s medium/F-12 nutrient
(DMEM/F12), L-glutamine, horse serum, penicillin/streptomycin/fun-
gizone mixture, an NF-jB DNA–protein-binding detection system,
and Trizol were purchased from Gibco BRL (Grand Island, NY,
USA). pELAM-Luc containing the NF-jB site construct was a gener-
ous gift from Dr. Youngmi Kim of Asan Hospital, University of Ulsan,
Seoul, Korea. Anti-COX-2 and anti-p65 antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA), and secondary anti-
bodies were purchased from Zymed Laboratories (San Francisco, CA,
USA). BCA protein assay reagents were obtained from Pierce (Rock-
ford, IL, USA), and [a-32P]CTP and [a-32P]ATP were purchased fromNEN Life Science Products (Boston, MA, USA). ExpressHyb hybrid-
ization buﬀer solution was obtained from Clontech (Palo Alto, CA,
USA). Transfection reagents and protease inhibitor cocktail were ob-
tained from Boehringer (Mannheim, Germany). TPA was the product
of Alexis (San Diego, CA, USA). ECL reagent, a prostaglandin E2
(PGE2) enzyme immunoassay kit, and a random primer labeling system
were obtained from Amersham Pharmacia Biotech (Buckinghamshire,
UK). Human cox-2 cDNA (1.8 kb) was kindly supplied by Prof. Daniel
Hwang (ARS,USDA,Davis, CA, USA). Human b-actin cDNA (548 bp)
was obtained using PCR. All other chemicals used were of analytical
grade or the highest grade available.
2.3. Cell culture
MCF10A cells were maintained at 37 C in a humidiﬁed atmosphere
of 5% CO2/95% air in DMEM/F12 medium supplemented with 5%
heat-inactivated horse serum, 10 lg/ml insulin, 100 ng/ml cholera tox-
in, 0.5 lg/ml hydrocortisone, 20 ng/ml recombinant human epithelial
growth factor, 2 mM L-glutamine, and 100 lg/ml penicillin/streptomy-
cin/fungizone mixture. Cells were grown to 60–80% conﬂuence and
trypsinized with 0.05% trypsin containing 2 mM EDTA.
2.4. Western blot analysis of COX-2
MCF10A cells (2 · 106) were plated on 100-mm culture dishes and
grown to 80% conﬂuence. The cells were treated for 4 h with TPA
(60 nM) alone or together with hirsutenone or TPCK. The cells were
scraped and treated with RIPA lysis buﬀer (150 mM NaCl; 0.5% Tri-
ton X-100; 50 mM Tris–HCl, pH 7.4; 25 mM NaF; 20 mM EGTA;
1 mM DTT; 1 mM Na3VO4; and a protease-inhibitor-cocktail tablet)
for 40 min on ice followed by centrifugation at 14800 · g for 30 min.
The protein concentration of the supernatant was measured using
the BCA reagent. Protein (30 lg) was loaded on a 12% sodium dodecyl
sulfate–polyacrylamide electrophoresis (SDS–PAGE) gel and electro-
transferred onto a polyvinylidene diﬂuoride membrane in Tris–glycine
buﬀer (pH 8.4) containing 20% methanol. The membrane was then
blocked in 5% fat-free dry milk in phosphate-buﬀered saline (PBS)
with 0.1% Tween-20 for 1 h. Membranes were ﬁrst incubated with goat
polyclonal anti-COX-2 or rabbit polyclonal anti-p65 (each diluted
1:1000 in 3% fat-free milk/PBS solution) for 2 h at room temperature.
After three 5-min washes with PBS/0.1% Tween-20, the mem-
branes were incubated with an 1:5000-diluted horseradish-peroxidase-
conjugated secondary antibody for 1 h. The transferred proteins were
visualized with the ECL Western blot detection system according to
the manufacturer’s instructions.
2.5. Northern blot analysis of cox-2 mRNA expression
MCF10A cells (2 · 106) were plated on 100-mm culture dishes and
grown to 80% conﬂuence. MCF10A cells were treated for 4 h with
TPA (60 nM) alone or together with hirsutenone. The total RNA
was isolated from cell monolayers using Trizol. Total RNA (6 lg)
was electrophoresed on a formaldehyde-containing 1.2% agarose gel
and transferred to nylon membranes. After ultraviolet-light-induced
cross-linking, membranes were prehybridized for 30 min in the Expres-
sHyb hybridization solution and hybridized for 1 h at 65 C with radi-
olabeled DNA probes for human cox-2 cDNA and b-actin cDNA.
After hybridization, membranes were washed twice for 30 min at room
temperature in SDS solution. Washed membranes were then subjected
to autoradiography. Cox-2 and b-actin cDNA probes were labeled
with [a-32P]CTP using a random primer kit.
2.6. Measurement of PGE2 production
MCF10A cells (5 · 105) were plated on six-well dishes and grown to
80% conﬂuence in 2 ml of growth medium. The cells were treated for
6 h with TPA (60 nM) alone or together with hirsutenone. The
amounts of PGE2 released into media were measured using the
PGE2 enzyme immunoassay kit.
2.7. Determination of the COX-2 enzyme activity
MCF10A cells (5 · 105) were plated on six-well dishes and grown to
80% conﬂuence in 2 ml of growth medium. After the cells were treated
with TPA (60 nM) for 4 h for maximal expression of COX-2 protein,
the media were changed and hirsutenone was added. Amounts of
PGE2 released into media were measured 2 h later using the PGE2 en-
zyme immunoassay kit.
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MCF10A cells (5 · 105) were plated on six-well dishes and grown to
90% conﬂuence in 2 ml of growth medium. The cells were maintained in
serum-free media for an additional 24 h with TPA (60 nM) alone or to-
gether with hirsutenone or TPCK. Conditioned medium was collected
and concentrated at 10000 · g for 30 min in a SpeedVac concentrator
(Savant, E-C Instruments, Niantic, CT, USA). The protein concentra-
tion was measured using BCA protein assay reagents. Equal amounts
of conditioned media were mixed with nonreducing sample buﬀer, incu-
bated for 15 min at room temperature, and then electrophoresed on
10% SDS–PAGE gels containing 1 mg/ml gelatin. After electrophore-
sis, the gels were washed with 2.5% Triton X-100 twice for 30 min,
rinsed three times for 30 min with a 50 mM Tris–HCl buﬀer (pH 7.6)
containing 5 mM CaCl2, 0.02% Brij-35, and 0.2% sodium azide, and
then incubated overnight at 37 C. The gels were stained with 0.5%
Coomassie brilliant blue R-250 solution containing 10% acetic acid
and 20% methanol for 30 min, and then destained with 7.5% acetic acid
solution containing 10%methanol. Areas of gelatinase activity were de-
tected as clear bands against the blue-stained gelatin background.
2.9. Invasion assay
An in vitro invasion assay was performed using a 24-well Transwell
unit with polycarbonate ﬁlters having a diameter of 6.5 mm and a pore
size of 8.0 lm (Corning Costar, Cambridge, MA, USA). The lower side
of the ﬁlter was coated with 10 ll of 0.5 mg/ml type I collagen, and the
upper side was coated with 10 ll of 0.5 mg/ml reconstituted basement
membrane substance (Matrigel; Collaborative Research, Lexington,
KY, USA). The coated ﬁlters were air dried for 1 h before the assay.
The lower compartment was ﬁlled with 600 ll of media containing
0.1% bovine serum albumin. MCF10A cells (5 · 104) were resuspended
with TPA (60 nM) alone or together with hirsutenone or TPCK in
100 ll of medium and placed in the upper part of the Transwell plate.
The cells were then incubated for 24 h in a humidiﬁed atmosphere of
5% CO2 at 37 C. Cells were ﬁxed with methanol and stained with
hematoxylin for 10 min followed brieﬂy by eosin. Cells on the upper
surface of the ﬁlter were removed mechanically by wiping with a cotton
swab, and the invasive phenotypes were determined by counting cells
that migrated to the lower side of the ﬁlter under light microscopy at
400· magniﬁcation. Thirteen ﬁelds were counted for each assay.
2.10. Wound migration assay
MCF10A cells (5 · 105) were plated on six-well dishes and grown to
90% conﬂuence in 2 ml of growth medium. The cells were damaged
with a 2-mm-wide tip. The cells were treated with TPA (60 nM) alone
or together with hirsutenone or TPCK. The cells were allowed to mi-
grate, and photographs were taken through an inverted microscope
(40· magniﬁcation).
2.11. Transient transfection and luciferase reporter gene assay
MCF10A cells (5 · 105) were plated on six-well dishes and grown to
60% conﬂuence in 2 ml of growth medium. The cells were transiently
transfected with 2.5 lg of plasmid pELAM-Luc containing the NF-
jB site construct ligated to the luciferase gene and 1 lg of
pCDNA3.1/hisB/lacZ (coding galactosidase for normalization of lucif-
erase activity) using the transfection reagent DOTAP according to the
manufacturer’s instructions. After overnight transfection, the cells
were treated for 6 h with TPA (60 nM) alone or together with hirsute-
none. The cells were then washed twice with cold PBS and lysed with
reporter lysis buﬀer (Promega). After vortex mixing and centrifugation
at 12000 · g for 1 min at 4 C, the supernatant was stored at 70 C
until used in the luciferase assay. Twenty milliliters of cell extract
and 100 ll of the luciferase assay reagent were mixed at room temper-
ature and placed in a luminometer (AutoLumat LB 953, EG&G Bert-
hold, Bad Wildbad, Germany) for detecting the light produced.
2.12. Electrophoretic mobility shift assay for determining NF-jB
DNA-binding activity
MCF10A cells (2 · 106) were plated on 100-mm culture dishes and
grown to 80% conﬂuence. The cells were treated for 30 min with
TPA (60 nM) alone or together with hirsutenone or TPCK. Cells were
gently washed twice with ice-cold PBS, scraped in 1 ml of PBS, and
centrifuged at 12000 · g for 30 s at 4 C. Pellets were suspended in
400 ll of hypotonic buﬀer (10 mM HEPES, pH 7.8; 10 mM KCl;2 mM MgCl2; 1 mM DTT, 0.1 mM EDTA; and 0.1 mM PMSF) for
15 min on ice, and 25 ll of 10% Nonidet P-40 solution was added
for 5 min. The mixture was then centrifuged at 14800 · g for 3 min.
The supernatant (i.e., the cytosolic fraction) was kept for Western blot
analysis. The nuclei were washed once with 400 ll of PBS and then sus-
pended in 100 ll of buﬀer (50 mM HEPES, pH 7.8; 50 mM KCl,
300 mM NaCl; 0.1 mM EDTA; 1 mM DTT; 0.1 mM PMSF; and
10% glycerol) for 20 min on ice and centrifuged at 14800 · g for
5 min. The supernatant containing nuclear proteins was collected
and stored at 70 C after determination of the protein concentration.
An electrophoretic mobility shift assay was performed using a DNA–
protein-binding detection kit (Gibco BRL) for NF-jB binding accord-
ing to the manufacturer’s protocol. Brieﬂy, the NF-jB oligonucleotide
probe (5 0-AGT TGA GGG GAC TTT CCC AGG C-3 0) was labeled
with [a-32P]ATP by T4 polynucleotide kinase and puriﬁed on a Nick
column. The binding reaction was performed in 25 ll of the mixture
containing 5 ll of incubation buﬀer (10 mM Tris–HCl, pH 7.5;
100 mM NaCl; 1 mM DTT; 1 mM EDTA; 4% (v/v) glycerol; and
0.1 mg/ml sonicated salmon sperm DNA), 10 lg of nuclear extracts,
and the labeled probe at 100000 cpm. After 30 min of incubation at
room temperature, 2 ll of 0.1% bromophenol blue was added and
samples were electrophoresed on a 6% nondenaturing polyacrylamide
gel at 150 V. Finally, the gel was dried and exposed to an X-ray ﬁlm.
2.13. Statistical analysis
Statistical signiﬁcance was assessed using one-way analysis of vari-
ance followed by two-tailed Dunnett’s t-test, with the level of signiﬁ-
cance set at p < 0.01.3. Results
3.1. Hirsutenone suppressed the TPA-induced expression and
activity of COX-2
In a preliminary study, the expression of COX-2 and cox-2
mRNA peaked at 4 and 2 h, respectively, in MCF10A cells
after the TPA (60 nM) stimulation (data not shown). In the
present study, we evaluated the ability of hirsutenone to inhibit
TPA-induced COX-2 expression in MCF10A cells. Treatment
of the cells with hirsutenone resulted in a concentration-depen-
dent suppression of COX-2 expression at both the protein and
mRNA levels (Fig. 2A and B). Hirsutenone alone did not
inﬂuence the constitutive expression of COX-2 in MCF10A
cells (data not shown).
3.2. Hirsutenone inhibited TPA-induced PGE2 synthesis and
COX-2 catalytic activity
In parallel with COX-2 downregulation, hirsutenone
strongly inhibited TPA-induced PGE2 production (Fig. 2C).
We also investigated the eﬀect of hirsutenone on activity of
COX-2 in MCF10A cells. In this experiment, cells were previ-
ously stimulated with TPA to induce COX-2, and hirsutenone
was added after replacement of media to remove any residual
TPA. As shown in Fig. 2D, hirsutenone also strongly sup-
pressed COX-2 catalytic activity.
3.3. Hirsutenone inhibited TPA-induced upregulation of
MMP-9, invasiveness, and motility
Recent studies have suggested that MMPs play a key role in
both the promotion and progression processes of breast carci-
nogenesis [14–16]. A previous report described that TPA acti-
vated MMP-9 in MCF10A cells, but the underlying
mechanisms were not clariﬁed [17]. As shown in Fig. 3A, the
gelatinolytic activity of MMP-9 – but not of MMP-2 – was
markedly increased in TPA-treated MCF10A cells, indicating
a preferential upregulation of MMP-9 by TPA in MCF10A
Fig. 2. Eﬀects of hirsutenone on TPA-induced upregulation of COX-2
in MCF10A cells. (A) Hirsutenone downregulates TPA-induced COX-
2 expression. MCF10A cells were treated for 4 h with TPA (60 nM)
alone or together with hirsutenone at various concentrations (12, 25,
and 50 lM). COX-2 expression was determined by Western blot
analysis as described in Section 2. The data are representative of three
independent experiments. (B) Hirsutenone inhibits the TPA-induced
cox-2mRNA expression. MCF10A cells were treated for 2 h with TPA
(60 nM) alone or together with hirsutenone at various concentrations
(12, 25, and 50 lM). Total RNA (6 lg) was analyzed by Northern blot
analysis using the [a-32P]-labeled cox-2 cDNA probe. As an internal
control, the b-actin mRNA level was analyzed on the same replicated
blot. The data are representative of three independent experiments. (C)
Hirsutenone suppresses TPA-induced induction of PGE2 synthesis.
MCF10A cells were treated with vehicle, TPA alone or TPA plus
hirsutenone (25 and 50 lM) for 6 h. The medium was collected to
determine the production of PGE2 using an enzyme immunoassay.
Data are means ± S.D. from three independent experiments. (D)
Hirsutenone directly inhibits COX-2 enzyme activity. MCF10A cells
were initially treated with vehicle (striped column) or TPA for 4 h.
After TPA stimulation of COX-2, fresh medium containing hirsute-
none (25 and 50 lM) was added, and incubation was continued for
additional 2 h. The medium was then collected to determine the
production of PGE2 using an enzyme immunoassay. Data are
means ± S.D. from three independent experiments. \Signiﬁcantly
diﬀerent from the group treated with TPA alone (P < 0.01).
Fig. 3. Eﬀects of hirsutenone on TPA-induced upregulation of MMP-
9, invasion, and motility in MCF10A cells. (A) Hirsutenone inhibits
TPA-induced expression of MMP-9. MCF10A cells were treated for
24 h with TPA (60 nM) alone or together with hirsutenone at various
concentrations (12, 25, or 50 lM). The level of MMP-9 (Mr = 92000)
secreted was determined by gelatin zymography as described in Section
2. The data are representative of three independent experiments. (B)
Hirsutenone inhibits the TPA-induced invasive phenotype develop-
ment. MCF10A cells were treated for 24 h with TPA (60 nM) alone or
together with hirsutenone at 25 or 50 lM. An in vitro invasion assay
was performed using a 24-well Transwell unit with polycarbonate
ﬁlters having a diameter of 6.5 mm and a pore size of 8.0 lm, and the
number of invading cells per ﬁeld was counted under light microscopy.
Data are means ± S.D. from three independent experiments. (C)
Hirsutenone inhibits the TPA-induced migrative phenotype as assessed
by the wound-migration assay. After pretreatment of cells with
mitomycin C (25 lg/ml) for 30 min, a line of cells in the conﬂuent
monolayer was scratch-damaged. MCF10A cells were treated with
TPA (60 nM) alone or together with hirsutenone (25 or 50 lM), and
cell motility was examined under light microscopy (40· magniﬁcation)
at the indicated time points. Circle, control; open circle, TPA-treated;
triangle, TPA + 25 lM hirsutenone; open triangle, TPA + 50 lM
hirsutenone. Data are means ± S.D. from three independent experi-
ments. \Signiﬁcantly diﬀerent from the group treated with TPA alone
(P < 0.01).
388 J.-H. Kim et al. / FEBS Letters 580 (2006) 385–392cells. Invasive and migrative phenotypes of MCF10A cells
were also signiﬁcantly increased by TPA (Fig. 3B and C), sug-
gesting that the activation of MMP-9 is essential for develop-
ment of invasive/migrative phenotypes in TPA-treated
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tion of MMP-9 in MCF10A cells in a dose-dependent manner
(Fig. 3A). The invasive and migrative phenotypes of TPA-trea-
ted MCF10A cells were signiﬁcantly inhibited by hirsutenone
(Fig. 3B and C). Survival of the cells treated with hirsutenone
for up to 24 h was comparable to that of cells at 0 h as deter-
mined by the MTT assay (data not shown), indicating that the
inhibition of invasion and motility was not due to hirsutenoneFig. 4. Hirsutenone inhibited TPA-induced NF-jB activation, p65 translocat
induced NF-jB activation. MCF10A cells were exposed to TPA alone or tog
incubated with an isotope-labeled oligo NF-jB probe. The NF-jB–DNA co
assay was performed as described in Section 2. The data are representative of
p65 translocation. Cells were exposed to TPA alone or together with hirsuten
were assayed by Western blot analysis for the detection of p65 as descri
experiments. (C) Hirsutenone suppresses the TPA-induced NF-jB gene tran
ligated to luciferase gene) vector was transiently transfected to MCF10A cel
column) or TPA and hirsutenone (12 and 50 lM) for 4 h. The luciferase repo
independent experiments. \Signiﬁcantly diﬀerent from the group treated withcytotoxicity. Hirsutenone alone did not aﬀect the basal levels
of MMPs, invasiveness, and motility in MCF10A cells (data
not shown).
3.4. Hirsutenone inhibited TPA-induced nuclear translocation,
DNA binding and transcriptional activity of NF-jB
Since NF-jB plays a privotal role in regulating the expres-
sion of genes encoding proteins involved in inﬂammationion, and NF-jB transcriptional activity. (A) Hirsutenone inhibits TPA-
ether with hirsutenone (12 or 50 lM) for 30 min. Nuclear extracts were
mplex is indicated by the arrowhead. An electrophoretic mobility shift
three independent experiments. (B) Hirsutenone inhibited TPA-induced
one at (12 or 50 lM) for 30 min. Fractionated nuclear extracts (30 lg)
bed in Section 2. The data are representative of three independent
scriptional activity. pELM-Luc (containing the NF-jB site construct
ls. After overnight transfection, cells were treated with vehicle (striped
rter assay is described in Section 2. Data are means ± S.D. from three
TPA alone (P < 0.01).
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press the activation of this transcription factor in TPA-treated
MCF10A cells. TPA treatment led to pronounced increase in
nuclear translocation, DNA binding and transactivation of
NF-jB (Fig. 4). As shown in Fig. 4A and B, treatment with
50 lM hirsutenone inhibited the TPA-stimulated activation
of NF-jB and blocked the translocation of p65, the function-
ally active subunit, to the nucleus.
To determine the NF-jB transcriptional activity, we trans-
fected MCF10A cells with a luciferase reporter plasmid har-
bouring the NF-jB promoter region ligated to a luciferase
reporter gene. When MCF10A cells transfected with a lucifer-
ase reporter plasmid containing the NF-jB promoter region li-
gated to a luciferase reporter gene were incubated with TPA
for 6 h, the luciferase activity was signiﬁcantly higher than that
in vehicle-treated control cells (Fig. 4C). The TPA-mediated
increase in the luciferase activity was attenuated by hirsute-
none in a dose-dependent manner (Fig. 4C).
3.5. TPA-induced upregulation of COX-2 and MMP-9 was
suppressed by a NF-jB inhibitor
We next investigated the functional signiﬁcance of the NF-
jB tansactivation in TPA-induced upregulation of COX-2
and MMP-9 in MCF10A cells. As shown in Fig. 5A and B,
treatment with TPCK, an inhibitor of NF-jB, abolished theFig. 5. Role of NF-jB in the TPA-induced upregulation of COX-2 and MM
the TPA-induced COX-2 expression. COX-2 expression was determined
representative of three independent experiments. (B) TPCK inhibits the T
determined by gelatin zymography. The data are representative of three in
phenotype. An in vitro invasion assay was performed using a 24-well Transw
pore size of 8.0 lm, and the number of invading cells per ﬁeld was counted u
phenotype. Wound migration assay: after pretreatment of cells with mitomyci
damaged. Cell motility was examined under light microscope (40·magniﬁcat
and 10 lM in all assays. Circle, control; open circle, TPA-treated; triangle, T
TPCK. Data are means ± S.D. from three independent experiments. \SigniﬁTPA-induced upregulation of COX-2 and MMP-9 in a con-
centration-dependent fashion. Treatment with TPCK almost
completely inhibited the invasive and migrative phenotype of
TPA-treated MCF10A cells (Fig. 5C and D). Under these
experimental conditions, the cell viability was not aﬀected by
TPCK treatment (data not shown), indicating that the inhibi-
tion of invasion and motility was not due to cytotoxicity of this
NF-jB inhibitor. TPCK alone did not aﬀect the basal levels of
COX-2, MMP-9, invasiveness, and motility in MCF10A cells
(Fig. 5). Taken together, the above ﬁndings suggest that hirsu-
tenone inhibits the TPA-induced upregulation of COX-2 and
MMP-9 by suppressing the activation of NF-jB in human
mammary epithelial cells, which would contribute to the sup-
pression of the invasive and migrative phenotype.4. Discussion
Abnormal upregulation of COX-2 has been frequently ob-
served in various malignancies including those of the breast,
esophagus, stomach, pancreas, lung, colon, skin, urinary blad-
der, and prostate (reviewed in [2]). In addition, overexpression
of COX-2 in genetically engineered mice led to enhanced
tumorigenesis, while knocking out COX-2 resulted in reduced
tumor formation and progression. Epidemiological studiesP-9, invasion, and motility in MCF10A cells. (A) TPCK downregulates
by Western blot analysis as described in Section 2. The data are
PA-induced invasive phenotype. The level of MMP-9 secreted was
dependent experiments. (C) TPCK inhibits the TPA-induced invasive
ell unit with polycarbonate ﬁlters having a diameter of 6.5 mm and a
nder light microscopy. (D) TPCK inhibits the TPA-induced migrative
n C (25 lg/ml) for 30 min, a line of cells in the conﬂuent monolayer was
ion) at the indicated time points. TPCK was used at concentrations of 5
PA + 5 lM TPCK; open triangle, TPA + 10 lM TPCK; square, 10 lM
cantly diﬀerent from the group treated with TPA alone (P < 0.01).
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administration of NSAIDs, such as aspirin and sulindac, and
the risk of colon [18] and breast cancer [19]. COX-2 may be di-
rectly involved in mammary carcinogenesis, since expression of
COX-2 is suﬃcient for formation of breast tumors in trans-
genic mice, and COX-2 selective inhibitors can suppress
tumorigenesis in rodent models of breast cancer (reviewed in
[16]). Thus, COX-2 is an important indicator in the genesis
of breast cancer and COX-2 inhibitors may be used for the
treatment and prevention of breast cancer. Therefore, hirsute-
none, which interferes with the signaling mechanism governing
the transcription of cox-2, is also anticipated to exhibit chemo-
preventive as well as antiinﬂammatory activities.
Numerous studies have shown that the levels of MMP-2
and/or MMP-9 correlate with the invasive phenotypes of can-
cer cells [5]. However, recent clinical studies suggest that MMP
inhibition does not necessarily confer beneﬁts over conven-
tional therapies [7]. One plausible reason is that MMP activity
is required preferentially for rapidly proliferating and invading
tumors rather than for preexisting tumors. As MMPs are
apparently involved in breast cancer promotion and dissemi-
nation as well as progression, inhibition of these proteinases
may be of value not only in blocking metastasis of established
tumors but also in preventing breast cancer in the earlier stage
(reviewed in [20]). As representative members of the MMP
family, MMP-9 and MMP-2 play a key role in the degradation
of type IV collagen that acts as the backbone of cellular base-
ment membrane. While MMP-2 is constitutively expressed in
the tissues as a latent 72-kDa proenzyme, MMP-9, like the
majority of other MMPs, is synthesized and secreted upon
demand. Thus, most of previous studies suggest that TPA in-
duces MMP-9 rather than MMP-2 in various cell lines [21–
24]. However, a recent study has shown that treatment of
MCF-10A cells with transforming growth factor-beta leads
to rapid induction of MMP-2 as well as MMP-9 expression,
which may contribute to the manifestation of migrative and
invasive phenotypes [25]. Therefore, the diﬀerential expression
of aforementioned type IV collagenases is likely to be related
to the types of the stimuli and the cells. In the present study,
we have found that the inhibition of TPA-induced motility
and invasive phenotypes in MCF10A cells by hirsutenone is
attributable to the suppression of MMP-9. The inhibition of
MMP activity by hirsutenone may prevent the relatively early
stage of carcinogenesis, particularly the tumor promotion pro-
cess before the malignancy manifests [8].
Previous studies have shown that TPA induces upregulation
of COX-2 [13] and MMP-9 [17] in MCF10A cells, but the
underlying molecular mechanisms remain largely unresolved.
The NF-jB complexes are activated by oxidative stress, onco-
genes, ultraviolet light, bacteria, inﬂammatory cytokines, and
phorbol esters, and regulates transcriptional initiation of di-
verse sets of genes whose products are important in mediating
inﬂammatory responses [26]. The importance of NF-jB in
mediating proinﬂammatory and carcinogenic events is also evi-
dent from experiments with knockout animals, suggesting that
this transcription factor is a suitable target for developing anti-
inﬂammatory and anticarcinogenic agents. The COX-2 and
MMP-9 genes, but not MMP-2, in mice and humans have
NF-jB binding sites in the 5 0 region of their promoters [27–
30]. In this study, hirsutenone attenuated the TPA-induced
activation of NF-jB. We assume that hirsutenone suppresses
TPA-induced upregulation of COX-2 and MMP-9 by blockingNF-jB in MCF10A cells. The NF-jB-speciﬁc inhibitor TPCK
abrogated TPA-induced upregulation of COX-2 and MMP-9,
lending support to the above assumption. Besides mitigating
the TPA-induced upregulation of COX-2 and MMP-9, TPCK
treatment almost completely inhibited the invasive and the
migrative phenotype of TPA-treated MCF10A cells.
NF-jB activation is primarily regulated via the mitogen-
activated protein kinase (MAPK) pathway. There are three
distinct groups of well-characterized major MAPK subfamily
members: (i) extracellular-signal-regulated protein kinase, (ii)
p38 MAPKs, which are serine/threonine protein kinases, and
(iii) c-Jun NH2-terminal kinase/stress-activated protein kinase.
The induction of MMPs and COX-2 was abolished by phar-
macological inhibition [31–33] and dominant-negative knock-
out [34,35] of the corresponding MAPKs, lending support to
the involvement of MAPK cascades in the upregulation of
COX-2 and MMPs in a manner that varies with the cell type
[3]. A recent study suggests that the protein kinase C-a and
Src kinase may mediate TPA-induced phosphorylation of
MAPK [36]. Additional studies will be needed to identify the
critical cellular molecules as prime targets for chemopreven-
tion with hirsutenone.
In summary, the above results suggest that hirsutenone
inhibits the activation of NF-jB involved in the upregulation
of COX-2 and MMP-9 in human mammary epithelial cells
stimulated with TPA, which may contribute to the chemopre-
ventive eﬀects exerted by this phytochemical.
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